Company news
Zai Lab Ltd. (HKEX:9688) news
Every Zai Lab Ltd. press release and news update in one place — announcements, filings coverage, and company updates for investors.
Press releases & updates
Zai Lab to Announce Second Quarter 2026 Financial Results and Recent Corporate Updates on August 6, 2026
July 22, 2026
Zai Lab Receives China NMPA Approval of TIVDAK® (tisotumab vedotin for injection) for the Treatment of Adult Patients with Recurrent or Metastatic Cervical Cancer
June 8, 2026
Zai Lab Receives U.S. FDA Fast Track Designation for Zocilurtatug Pelitecan (Zoci), a DLL3-Targeting ADC, for Treatment of Extrapulmonary Neuroendocrine Carcinomas (epNECs)
May 11, 2026
Zai Lab Announces First Quarter 2026 Financial Results and Recent Corporate Updates
May 7, 2026
Zai Lab to Announce First Quarter 2026 Financial Results and Recent Corporate Updates on May 7, 2026
April 22, 2026
Zai Lab Presents New Preclinical Data Suggesting ZL-1503, an IL-13/IL-31Rα Bispecific Antibody, Provides Rapid Itch Relief and Reduction in Inflammation in Atopic Diseases
April 18, 2026
Zai Lab Presents New Data Demonstrating Zocilurtatug Pelitecan (Zoci) Induces Rapid and Robust Intracranial Responses in Small Cell Lung Cancer with Brain Metastases and Promising Activity in Other Neuroendocrine Carcinomas
April 17, 2026
Boehringer Ingelheim and Zai Lab announce Collaboration on DLL3‑targeting T‑Cell Engager and ADC Combination in Small Cell Lung Cancer and Other Neuroendocrine Carcinomas
April 15, 2026
Zai Lab Announces Global Clinical Trial Collaboration and Supply Agreement to Evaluate Novel DLL3 ADC, Zocilurtatug Pelitecan, in Combination with a Bispecific T-cell Engager Therapy
April 1, 2026
Zai Lab to Present New Data on Three Internally Developed Oncology Candidates at AACR 2026, Including Zocilurtatug Pelitecan, a DLL3-Targeting Antibody-Drug Conjugate (ADC)
March 17, 2026
Zai Lab Announces Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate Updates
February 26, 2026
Zai Lab to Announce Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate Updates on February 26, 2026
February 10, 2026
Zai Lab Highlights Strategic Priorities and Global Pipeline Progress at 44th Annual J.P. Morgan Healthcare Conference
January 13, 2026
Zai Lab Announces National Medical Products Administration (NMPA) Approval of AUGTYRO™ (repotrectinib) for Patients with NTRK-Positive Solid Tumors
January 6, 2026
Zai Lab to Present at 44th Annual J.P. Morgan Healthcare Conference
January 5, 2026
Zai Lab Announces Approval of COBENFY (xanomeline and trospium chloride) in China, a First-in-Class Therapy for Schizophrenia
December 23, 2025
Zai Lab Announces Dosing of First Participant in Global Phase 1/1b study of ZL-1503, an IL-13/IL-31R Bispecific Antibody for the Treatment of Atopic Dermatitis
December 8, 2025
Zai Lab Announces Updates to China’s National Reimbursement Drug List
December 7, 2025
Zai Lab Announces Third Quarter 2025 Financial Results and Recent Corporate Updates
November 6, 2025
Zai Lab Announces Participation in Investor Conferences in November and December 2025
October 31, 2025
Zai Lab Announces Updated Phase 1 Data for Zocilurtatug Pelitecan (formerly ZL-1310), Demonstrating Potential as a First-in-Class/Best-in-Class DLL3-Targeted ADC for Small Cell Lung Cancer, and Initiation of Global Phase 3 Registrational Study
October 24, 2025
Zai Lab to Announce Third Quarter 2025 Financial Results and Recent Corporate Updates on November 6, 2025
October 15, 2025
Zai Lab Announces Oral Presentation of Updated Data from Global Phase 1 Trial of Zocilurtatug Pelitecan (ZL-1310), a Potential First-in-Class DLL3-Targeted ADC, at 2025 AACR-NCI-EORTC Conference
October 13, 2025
Zai Lab Announces Approval of TIVDAK® for Patients with Recurrent or Metastatic Cervical Cancer in Hong Kong
September 1, 2025
Zai Lab Announces Participation in Investor Conferences in September 2025
August 28, 2025
Zai Lab Announces China National Medical Products Administration Grants Innovative Medical Device Designation for Tumor Treating Fields for Patients with Pancreatic Cancer
August 19, 2025
Zai Lab Establishes Oncology Scientific Advisory Board
August 13, 2025
Zai Lab Announces Second Quarter 2025 Financial Results and Recent Corporate Updates
August 7, 2025
Zai Lab to Announce Second Quarter 2025 Financial Results and Recent Corporate Updates on August 7, 2025
July 10, 2025
Zai Lab Announces Positive Topline Phase 3 Results for Bemarituzumab in Fibroblast Growth Factor Receptor 2b (FGFR2b) Positive First-Line Gastric Cancer
June 30, 2025
Zai Lab Presents New Preclinical Data for ZL-1503, an IL-13/IL-31R Bispecific Antibody for the Treatment of Atopic Dermatitis, at EAACI Congress 2025
June 13, 2025
Zai Lab Presents Positive Phase 1 Data for ZL-1310, a DLL3-Targeted ADC, Demonstrating Robust Anti-Tumor Activity and Safety in Patients with Extensive-Stage Small Cell Lung Cancer at 2025 ASCO Annual Meeting
June 2, 2025
Zai Lab and Novocure Announce Results From the Phase 3 PANOVA-3 Trial of Tumor Treating Fields (TTFields) Therapy for Pancreatic Cancer to be Presented at 2025 ASCO Annual Meeting
May 31, 2025
Zai Lab Announces Participation in Investor Conferences in June 2025
May 30, 2025
Zai Lab Receives U.S. FDA Fast Track Designation for ZL-1310, a DLL3-Targeted Antibody-Drug Conjugate, for Treatment of Extensive-Stage Small Cell Lung Cancer
May 19, 2025
Zai Lab Announces First Quarter 2025 Financial Results and Recent Corporate Updates
May 8, 2025
Zai Lab Presents Data Highlighting Potential of Internally Developed, Next-Generation Oncology Therapies at AACR 2025
April 25, 2025
Zai Lab to Present Data from Phase 1 Trial of DLL3-Targeted Antibody-Drug Conjugate (ADC) ZL-1310 at 2025 ASCO Annual Meeting
April 23, 2025
Zai Lab Announces Acceptance of Supplemental New Drug Application for Repotrectinib for Patients with NTRK-Positive Solid Tumors
April 21, 2025
Zai Lab to Announce First Quarter 2025 Financial Results and Recent Corporate Updates on May 8, 2025
April 14, 2025
Zai Lab to Present New Data from Internally Developed, Next-Generation Oncology Candidates at AACR 2025 Annual Meeting
March 26, 2025
Zai Lab Announces Acceptance of Biologics License Application for TIVDAK for the Treatment of Patients with Recurrent or Metastatic Cervical Cancer
March 12, 2025
Zai Lab Announces Participation in Investor Conferences in March 2025
March 3, 2025
Zai Lab Announces Fourth Quarter and Full Year 2024 Financial Results and Recent Corporate Updates
February 27, 2025